Attendee search 

Kymeris Therapeutics (Canada) has exlusive license to a ground-breaking cell-based immunotherapeutic product for clinical development in cancer. This multivalent anti-cancer platform integrates multiple mechanisms in one modifiable platform. The product is tumor-homing, disables the local tumor defenses and expresses encoded biodrugs in the cancer - but not systemically.

*  We are seeking partners with small molecule or antibody (or any encodable peptide or protein) that would have an enabling platform compared to intravenous or intratumoral formulations.

*  We are also seeking strategic investors in the platform that has extremely high potential in future products, adaptable against almost any solid cancer.

------------------------------------------------------------------

The platform can enable, or enhance, additional small molecule, antibody, peptide or cytokine agents.  It is a preclinical late-stage firm that has discovered and developed a First-in-Class immunotherapeutic platform based on non-pathogenic eukaryotes (nucleated cells, non-viral, non-bacterial). Our platform is original with the first scientific paper just published in November 2020 by the Journal of Immunotherapy of Cancer (BMJ), and our first scientific presentation at the 2020 Annual Meeting of the SITC where we presented recent report on a derivative that secreted human IL-15 within tumor, but devoid of serum detection of the cytokine.

The platform would be a paradigm shift from "reductive" (targeted, mono-mechanism) approaches, and can be encoded with additional molecular therapies to more comprehensively face the complex of solid cancer defenses. Encoding any biological agent (small molecule, antibody, antigen, cytokine...), could enable that agent for a wider scope of applications,  enhanced effect and much safer profile.  In addition, the platform shows abscopal effect, an ability to reach tumors after administration from a distance (subcutaneous or mucosal).

The platform has shown the following characteristics:

1. Tumor-tropism / Cancer-agnostic. Homing to tumor occurred in the absence of a cancer antigen marker (TAA or TSA), and may even work in tumors that are not easily "targetable", such as "cold", lacking cancer markers, heterogeneic or mutating tumors. One oncologist remarked, "This turns "cold" tumors "hot" ".The agents have had effect at distance from tumor site when administered subcutaneously or mucosally. 

 2. Tumor-infiltration + TME counteraction. The agents bear a specialized "universal key" to gain entry into mammalian cell in an active process; no specific  receptor needed. In addition, the agents are able to reprogram tolerogenic cells into a state of immune competence i.e. to overcome cancer-induced immune suppression within the tumor.

3. Intra-cancer delivery of any payload/s. Obligate intracellular microbes, the agents infect cancer cells and replicate, expressing encoded biodrugs. The replication continues as long as there is cancer tissue to infect and/or the TME has not been disabled.  Any agents outside of the TME were naturally cleared in under 10 days.